white → orange2
Not yet reviewed — this article is pending editorial review by Lyrea.
WARNINGDANGER OF DEATH
High doses alone or ordinary doses in combination with other depressants can fatally stop breathing.
Citation noticeOur citation system is being overhauled
References and citation markers may currently be incomplete, mismatched, or incorrect. This system is being rebuilt and reviewed before the full site launch.
Butyrfentanyl
Butyrfentanyl is a potent short-acting synthetic opioid and analog of fentanyl, possessing approximately one quarter of its parent compound's potency. It has no established clinical applications and is sold exclusively as a designer drug. One of the earliest references to this compound appears in documentation by The College on Problems of Drug Dependence. As with other fentanyl analogs, butyrfentanyl carries significant risk of respiratory depression and fatal overdose, demanding extreme caution.
Dosage & Duration
Dosage
Doses are population estimates that vary widely between individuals.
Threshold~400 µg
Light400-800 µg
Moderate800-1500 µg
Strong1.5-3 mg
Heavy3+ mg
This substance exhibits significantly greater potency compared to conventional opioids, making precise dose measurement and gradual titration essential for risk reduction.
Duration
After Effects1-4 hours
Subjective Effects
Legacy content. A statistically backed ontology from Mindstate Design Labs is coming soon.
Butyrfentanyl produces a short-acting opioid experience broadly comparable to that of fentanyl, though at roughly one quarter of its potency. The experience is dominated by analgesia, sedation, and opioid euphoria rather than any meaningful sensory alteration. Its effect profile mirrors that of other fentanyl analogs, including a pronounced risk of life-threatening respiratory depression at higher doses.
Physical
Physical effects center on pain relief and a heavy, sedated body feeling, accompanied by itching and nausea. Respiratory depression scales with dose and can become life-threatening.
Cognitive
The headspace is a typical opioid state centered on euphoric contentment and relaxation, without notable perceptual or hallucinatory components.
Pharmacology
Pharmacodynamics
Butyrfentanyl acts as an agonist at μ-opioid receptors. In radioligand displacement assays using [3H]fentanyl, it exhibits a Ki of 32 ± 4.1 nM, indicating substantially lower binding affinity than fentanyl itself (Ki 1.06 ± 0.15 nM) and roughly one quarter of its potency as an opioid agonist.
Pharmacokinetics
Butyrfentanyl is rapidly cleared from the body. In studies of urinary excretion following injection, nearly all of the administered dose was excreted or metabolized within the first 3 hours, with only very low concentrations detectable thereafter.
Metabolitesnone documented yet
Interactions
Interactions not written up yet
An unlisted combination is an unknown one, not a safe one. Check a dedicated combination chart before mixing.
Tolerance
Tolerance timelines are rules of thumb, not exact schedules, and vary widely between individuals and use patterns.
Cross Tolerance
Opioids (fentanyl, morphine, heroin, oxycodone, and other μ-opioid receptor agonists)
Harm Potential
Addiction & Dependence
Psychological
HighClassified as habit-forming. As a potent synthetic opioid and fentanyl analog, it carries significant abuse potential.
Toxicity
Respiratory
Can cause serious respiratory depression that may be life-threatening in overdose.
History & Culture
Butyrfentanyl first appears in scientific literature through documentation by the College on Problems of Drug Dependence, where it was referenced as an N-butyramide fentanyl analog. Pharmacological characterization of the compound—including analgesic efficacy studies, opioid receptor binding…
Legality
International
UN Single Convention on Narcotic Drugs 1961 (Schedule I, added March 2017)
By Country
Illegal4
United StatesIllegalButyrfentanyl, listed federally as butyryl fentanyl, is a Schedule I controlled substance under 21 C.F.R. § 1308.11(b)(26). It was temporarily placed in Schedule I effective May 12, 2016, permanently placed there effective April 20, 2018, and remained expressly listed in the eCFR text current on September 1, 2026. Unauthorized possession, manufacture, distribution, import, and export are prohibited, while DEA-registered or otherwise federally authorized activities such as research, instructional use, and chemical analysis may be permitted.
ChinaIllegalButyrfentanyl is expressly listed as item 109 of the 2025 Catalogue of Non-Medicinal Narcotic Drugs and Psychotropic Substances, under the English name Butyrylfentanyl and the chemical name N-(1-Phenethylpiperidin-4-yl)-N-phenylbutyramide. The substance has been controlled since 1 October 2015 and remains included in the current catalogue. Its production, purchase, sale, transport, use, storage, import, and export are prohibited, although experimental research may be conducted in accordance with the Regulations on the Administration of Narcotic Drugs and Psychotropic Substances.
SwitzerlandIllegalButyrfentanyl is a prohibited controlled substance in Switzerland's List d, where it has been listed by exact name since 1 October 2017. It had previously appeared as Butanoyl-Fentanyl in List e from 1 December 2015, before the 2017 amendment moved it to List d. Unauthorized manufacture, storage, transport, import, export, sale, supply, prescribing, possession, or acquisition can be punished by up to three years' imprisonment or a monetary penalty, although the Federal Office of Public Health may grant exceptional authorization to handle List d substances.
United KingdomIllegal (analog/blanket ban)Butyrfentanyl is a Class A controlled drug under the generic fentanyl provision in Schedule 2, Part I, paragraph 1(d) of the Misuse of Drugs Act 1971. Although it is not individually named, it is covered as a compound structurally derived from fentanyl by replacing the N-propionyl group with another acyl group. This generic provision has applied since 1 April 1987. Possession, possession with intent to supply, production, supply, offering to supply, importation and exportation are restricted, subject to applicable regulations, licences, statutory exceptions and defences.
References
Citations
- 我国管制毒品目录（2026年7月更新，540种+三大类）. ga.sz.gov.cn (n.d.). https://ga.sz.gov.cn/SZJDZX/SZBMFW/content/post_12898420.html1
- 非药用类麻醉药品和精神药品列管办法. gaj.panjin.gov.cn (n.d.). https://gaj.panjin.gov.cn/2015_10/08_00/content-235605.html1
- 麻醉药品和精神药品管理条例 (Regulations on the Administration of Narcotic Drugs and Psychotropic Substances), third revision. xzfg.moj.gov.cn (n.d.). https://xzfg.moj.gov.cn/front/law/detail?LawID=17441
- 三部门联合发布最新版《非药用类麻醉药品和精神药品目录》. btgaj.xjbt.gov.cn (n.d.). https://btgaj.xjbt.gov.cn/c/2025-07-28/8428464.shtml1
- 国家禁毒委召开新闻发布会宣布整类列管芬太尼类物质. gat.xinjiang.gov.cn (n.d.). https://gat.xinjiang.gov.cn/gat/jwyw/201904/351d88c2400d4f51961d48c44fd48492.shtml1
- Commission on Narcotic Drugs: Extract from the Report of the 38th WHO Expert Committee on Drug Dependence. unodc.org (n.d.). https://www.unodc.org/documents/commissions/CND/CND_Sessions/CND_59Reconvened/ECN72016_CRP13_V1610192.pdf12
- Betäubungsmittelverzeichnisverordnung (BetmVV-EDI), SR 812.121.11, consolidated text as at 13 March 2026. fedlex.data.admin.ch (n.d.). https://fedlex.data.admin.ch/filestore/fedlex.data.admin.ch/eli/cc/2011/363/20260313/de/html/fedlex-data-admin-ch-eli-cc-2011-363-20260313-de-html-3.html1
- BetmVV-EDI amendment of 18 August 2017 (AS 2017 5003). fedlex.data.admin.ch (n.d.). https://fedlex.data.admin.ch/filestore/fedlex.data.admin.ch/eli/oc/2017/539/de/pdf-a/fedlex-data-admin-ch-eli-oc-2017-539-de-pdf-a.pdf1
- Betäubungsmittelverzeichnisverordnung (BetmVV-EDI), SR 812.121.11, consolidated text as at 1 December 2015. fedlex.data.admin.ch (n.d.). https://fedlex.data.admin.ch/filestore/fedlex.data.admin.ch/eli/cc/2011/363/20151201/de/pdf-a/fedlex-data-admin-ch-eli-cc-2011-363-20151201-de-pdf-a.pdf1
- Betäubungsmittelkontrollverordnung (BetmKV), SR 812.121.1, consolidated text as at 23 January 2023. fedlex.admin.ch (n.d.). https://www.fedlex.admin.ch/filestore/fedlex.data.admin.ch/eli/cc/2011/362/20230123/de/html/fedlex-data-admin-ch-eli-cc-2011-362-20230123-de-html-3.html1
Article Status
Step 1 · Automated synthesisAn autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.
- Step 2 · First-pass reviewPending
Not yet reviewed — this article is pending editorial review by Lyrea.
- Step 3 · Citation reviewPending
No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.
Recent changes7 human edits · latest
Times are UTCNewest first
24 January 2026
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the Butyrfentanyl article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.
Wish to give generalised feedback? You can do so here.